Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- PMDA Unveils New International Strategy
June 30, 2015
- MHLW Global Strategy Aims at Regulatory Shortcut for Japan-OK’ed Drugs
June 29, 2015
- Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
- MHLW Approves Additional Indications for Radicut and Other Products
June 29, 2015
- 8 Members Exit Pharmaceutical Affairs Council
June 26, 2015
- LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
- Problems at Kaketsuken Remained Undetected Despite 21 On-Site Inspections over 10-Year Period: PMDA
June 26, 2015
- Univ. of Tokyo Prof. Tanabe Elected as Chuikyo Chairman
June 25, 2015
- HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
- AMED Initiates “Middle Molecule Drug Discovery” Project; Aims to Out-License Lead Compounds to Drug Makers
June 25, 2015
- Panel Begins Discussions on Revising Basic Guidelines for Measures against Hepatitis
June 25, 2015
- Drug Pricing Tomorrow: Ex-Chuikyo Chair Urges Pharma to Look at How to Refine Premium, Not Permanent Introduction
June 25, 2015
- Kaketsuken Likely to Face Administrative Penalty over GMP Violation
June 24, 2015
- LDP Begins Intraparty Deliberations on Economic, Fiscal Blueprint
June 24, 2015
- PMDA Beats Its Targets for Overall Review Time in FY2014
June 24, 2015
- Draft Growth Strategy Embraces Clinical Development Infrastructure, Drops Numerical Target for Sakigake System
June 23, 2015
- 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
- PMDA, AMED Plan to Enter Partnership Agreement; Share Information to Promote Commercialization of Seeds
June 23, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 8 - June 21
June 22, 2015
- AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…